FDAnews
www.fdanews.com/articles/198960-diffusion-pharmaceuticals-begins-phase-1-trial-of-oxygen-enhancing-drug-for-covid-19
COVID-19

Diffusion Pharmaceuticals Begins Phase 1 Trial of Oxygen-Enhancing Drug for COVID-19

September 11, 2020

Diffusion Pharmaceuticals has dosed its first two patients in a phase 1b trial of its synthetic carotenoid, trans sodium crocetinate (TSC), for hospitalized COVID-19 patients with low levels of oxygen in the blood.

The 24-patient trial at the Romanian National Institute of Infectious Diseases is evaluating TSC’s safety and tolerability and its effects on arterial blood oxygenation. Data from the trial will be used to guide a follow-on efficacy study to take place in the U.S. and Europe.

TSC has shown in preclinical models to increase oxygen availability and provide functional benefit for acute lung injury and hemorrhagic shock.

View today's stories